PATENT CLAIM ANALYSIS

Application Number: 15755435
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "233800"]

Abstract:
The present invention provides a chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amino acid glutamate and presents an advantageously high brain exposure upon oral administration, for the treatment or prevention of levodopa-induced dyskinesia. The present invention also provides an improved therapy of Parkinson's disease, using the chromone oxime derivative of formula (I) in combination with ievodopa.

Claim (Index 7):
The compound for use according to  claim 6 , wherein the compound of formula (I) has the (E)-configuration at the oxime group comprised in formula (I).

Metadata:
- Claim Count in Document: 47.0
- Percentile: 88.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15506941', '14113340', '14513488', '11762206', '14702242']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7925049660102162
- 35 USC 102 Novelty (BERT): 0.605299992862986
- Combined Prediction Score: 0.7737844686954933
- Mean Citation Score: 394.291842
- Max Citation Score: 618.9172
- Similarity Product: 421.35065291287896

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test